Sun Pharma’s ILUMYA wins FDA approval for psoriatic arthritis
In short
Sun Pharma’s ILUMYA got US FDA approval for adults with active psoriatic arthritis. The drug was already used for plaque psoriasis, so this expands what it can be used for.
This gives doctors and patients in the US another treatment option. The reporting does not say when sales will start or how much the change could add.
What the reporting says
Sun Pharma’s ILUMYA got US FDA approval for adults with active psoriatic arthritis, expanding use beyond plaque psoriasis. The reporting says this adds a new treatment option, but it does not state the launch timing, pricing or expected sales impact. The immediate consequence is broader label coverage for the drug in the US market.
Why it matters
The US FDA approval expands ILUMYA beyond plaque psoriasis to adults with active psoriatic arthritis. The reporting does not state launch timing, revenue impact or any safety details. The news matters to Sun Pharma because it broadens the drug’s US use, and to patients and doctors because it adds another treatment option.